Deng, Jiehui

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 770

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 594

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine

Cytokine Signaling Pathways and InteractionsSphingolipid Metabolism and Signaling

Cited by 395

Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms

Yang, A., Herter-Sprie, G., Zhang, H., Lin, E. Y., Biancur, D., Wang, X., Deng, J., Hai, J., Yang, S., Wong, K.-K., et al. (2018) · Cancer Discovery

Autophagy in Disease and TherapyPancreatic and Hepatic Oncology Research

Cited by 349

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 265

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Briere, D. M., Li, S., Calinisan, A., Sudhakar, N., Aranda, R., Hargis, L., Peng, D. H., Deng, J., Engstrom, L. D., Hallin, J., et al. (2021) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 168

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer

Deng, J., Thennavan, A., Dolgalev, I., Chen, T., Li, J., Marzio, A., Poirier, J. T., Peng, D. H., Bulatovic, M., Mukhopadhyay, S., et al. (2021) · Nature Cancer

Cancer Immunotherapy and BiomarkersAutophagy in Disease and Therapy

Cited by 140

Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer

Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 72

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer

Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 67

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K. H., Cao, S., Chouitar, J., Wu, J., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 57

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Ahronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., et al. (2025) · Cancer Research

Cancer Immunotherapy and BiomarkersHistone Deacetylase Inhibitors Research

Cited by 9